MS Trial Alert: Study of Oral Teriflunomide (HMR1726) Recruiting People with Relapsing Forms of MS Worldwide

Summary: Investigators worldwide are recruiting 1110 people with relapsing forms of multiple sclerosis (MS) for a study comparing two doses of teriflunomide (HMR1726), an investigational, oral MS medication, and inactive placebo. For the purposes of this study, "relapsing forms of MS" would include individuals who have experienced one MS attack in the past one year or two MS attacks in the past two years. The study, known as the “TOWER” study, is sponsored by Sanofi-Aventis.

Rationale: Multiple sclerosis occurs when the immune system attacks the brain and spinal cord. Teriflunomide is an agent that may decrease immune system activity in MS. Other studies of teriflunomide in MS are ongoing.

Eligibility and Details: People eligible for participation include individuals 18-55 years of age with relapsing forms of MS.

Participants will be randomly assigned to receive 7 mg teriflunomide, 14 mg or placebo once daily for a minimum of 48 weeks. The main goal of the study is to determine whether the study drug reduces the frequency of relapses significantly more than placebo. Other measures of the effectiveness will also be performed, and safety and tolerability will be monitored.

Contact: For further information, and to find out if this study is enrolling subjects at a site near you, please visit http://tower3.msstudies.com or call toll-free 1-866-565-0245. Sites will be enrolling in the following states:

Arizona
California
Colorado
Connecticut
Florida
Georgia
Iowa
Illinois
Indiana
Michigan
North Carolina
New Hampshire
New York
Ohio
Oklahoma
Oregon
Pennsylvania
Tennessee
Texas
Washington
Wisconsin
West Virginia